Encyclopedia of Signaling Molecules

2018 Edition
| Editors: Sangdun Choi

Casein Kinase II

  • Jacob P. Turowec
  • Nicole A. St. Denis
  • David W. LitchfieldEmail author
Reference work entry
DOI: https://doi.org/10.1007/978-3-319-67199-4_110


Historical Background

Protein kinase CK2 was isolated almost 60 years ago on the basis of its ability to phosphorylate the milk protein casein (Allende and Allende 1995; Venerando et al. 2014). As a result, it was originally designated “casein kinase II,” though this misnomer is less frequently used because of the lack of physiological significance for the phosphorylation of casein by CK2. Ironically, the enzyme/substrate relationship between CK2 and casein illustrates somewhat of a recurring theme. In this respect, over 50 years of research on CK2 has resulted in a compilation of a very large number of putative CK2 substrates, while the functional analysis of these phosphorylation events has lagged comparatively behind. In large part, the identification of many CK2 substrates has been promoted by its relatively simple and somewhat unique preference for acidic specificity determinants (S/T-X-X- E/D/pS/pY) (Meggio and Pinna 2003...

This is a preview of subscription content, log in to check access.


  1. Allende JE, Allende CC. Protein kinases. 4. Protein kinase CK2: an enzyme with multiple substrates and a puzzling regulation. FASEB J. 1995;9:313–23.PubMedCrossRefGoogle Scholar
  2. Bibby AC, Litchfield DW. The multiple personalities of the regulatory subunit of protein kinase CK2: CK2 dependent and CK2 independent roles reveal a secret identity for CK2beta. Int J Biol Sci. 2005;1:67–79.PubMedPubMedCentralCrossRefGoogle Scholar
  3. Canton DA, Litchfield DW. The shape of things to come: an emerging role for protein kinase CK2 in the regulation of cell morphology and the cytoskeleton. Cell Signal. 2006;18:267–75.PubMedCrossRefGoogle Scholar
  4. Dominguez I, Sonenshein GE, Seldin DC. Protein kinase CK2 in health and disease: CK2 and its role in Wnt and NF-kappaB signaling: linking development and cancer. Cell Mol Life Sci. 2009;66:1850–7.PubMedPubMedCentralCrossRefGoogle Scholar
  5. Duncan JS, Litchfield DW. Too much of a good thing: the role of protein kinase CK2 in tumorigenesis and prospects for therapeutic inhibition of CK2. Biochim Biophys Acta. 2008;1784:33–47.PubMedCrossRefGoogle Scholar
  6. Duncan JS, Gyenis L, Lenehan J, Bretner M, Graves LM, Haystead TA, Litchfield DW. An unbiased evaluation of CK2 inhibitors by chemoproteomics: characterization of inhibitor effects on CK2 and identification of novel inhibitor targets. Mol Cell Proteomics. 2008;7:1077–88.PubMedCrossRefGoogle Scholar
  7. Duncan JS, Turowec JP, Vilk G, Li SS, Gloor GB, Litchfield DW. Regulation of cell proliferation and survival: convergence of protein kinases and caspases. Biochim Biophys Acta. 2010;1804:505–10.PubMedCrossRefGoogle Scholar
  8. Duncan JS, Turowec JP, Duncan KE, Vilk G, Wu C, Luscher B, Li SS, Gloor GB, Litchfield DW. A peptide-based target screen implicates protein kinase CK2 in the global regulation of caspase signaling. Sci Signal. 2011;4:ra30.PubMedCrossRefGoogle Scholar
  9. Filhol O, Cochet C. Protein kinase CK2 in health and disease: Cellular functions of protein kinase CK2: a dynamic affair. Cell Mol Life Sci. 2009;66:1830–9.PubMedCrossRefGoogle Scholar
  10. Gyenis L, Litchfield DW. Protein kinase CK2: systematic relationships with other post-translation modifications. In: Protein kinase CK2: cellular function in normal and disease states. Cham: Springer; 2015. p. 183–96.Google Scholar
  11. Gyenis L, Duncan JS, Turowec JP, Bretner M, Litchfield DW. Unbiased functional proteomics strategy for protein kinase inhibitor validation and identification of bonafide protein kinase substrates: application to identification of EEF1D as a substrate for CK2. J Proteome Res. 2011;10:4887–901.PubMedPubMedCentralCrossRefGoogle Scholar
  12. Gyenis L, Kus A, Bretner M, Litchfield DW. Functional proteomics strategy for validation of protein kinase inhibitors reveals new targets for a TBB-derived inhibitor of protein kinase CK2. J Proteome. 2013;81:70–9.CrossRefGoogle Scholar
  13. Keller DM, Zeng X, Wang Y, Zhang QH, Kapoor M, Shu H, Goodman R, Lozano G, Zhao Y, Lu H. A DNA damage-induced p53 serine 392 kinase complex contains CK2, hSpt16 and SSRP1. Mol Cell. 2001;7:283–92.PubMedCrossRefGoogle Scholar
  14. Litchfield DW. Protein kinase CK2: structure, regulation and role in cellular decisions of life and death. Biochem J. 2003;369:1–15.PubMedPubMedCentralCrossRefGoogle Scholar
  15. Litchfield DW, Dobrowolska G, Krebs EG. Regulation of casein kinase II by growth factors: a re-evaluation. Cell Mol Biol Res. 1993;40:501–11.Google Scholar
  16. Meggio F, Pinna LA. One-thousand-and-one substrates of protein kinase CK2? FASEB J. 2003;17:349–68.PubMedCrossRefGoogle Scholar
  17. Messenger MM, Saulnier RB, Gilchrist AD, Diamond P, Gorbsky GJ, Litchfield DW. Interactions between protein kinase CK2 and Pin1: evidence for phosphorylation-dependent interactions. J Biol Chem. 2002;277:23054–64.PubMedCrossRefGoogle Scholar
  18. Niefind K, Guerra B, Ermakowa I, Issinger O-G. Crystal structure of human protein kinase CK2: insights into basic properties of the CK2 holoenzyme. EMBO J. 2001;20:5320–31.PubMedPubMedCentralCrossRefGoogle Scholar
  19. Niefind K, Raaf J, Issinger OG. Protein kinase CK2 in health and disease: protein kinase CK2: from structures to insights. Cell Mol Life Sci. 2009;66:1800–16.PubMedCrossRefGoogle Scholar
  20. Nunez de Villavicencio-Diaz T, Rabalski A, Litchfield DW. Protein kinase CK2: intricate relationships within regulatory cellular networks. Pharmaceuticals. 2017 (under review).Google Scholar
  21. Olsten ME, Litchfield DW. Order or chaos? An evaluation of the regulation of protein kinase CK2. Biochem Cell Biol. 2004;82:681–93.PubMedCrossRefGoogle Scholar
  22. Pierre F, Chua PC, O’Brien SE, Siddiqui-Jain A, Bourbon P, et al. Discovery and SAR of 5-(−3-chlorophenylamino)benzo[c][2,6]naphthyridine-8-carboxylic acid (CX-4945), the first clinical stage inhibitor of protein kinase CK2 for the treatment of cancer. J Med Chem. 2011;54:635–54.PubMedCrossRefGoogle Scholar
  23. Pinna LA, Allende JE. Protein kinase CK2 in health and disease: protein kinase CK2: an ugly duckling in the kinome pond. Cell Mol Life Sci. 2009;66:1795–9.PubMedCrossRefGoogle Scholar
  24. Pyerin W, Ackermann K. The genes encoding human protein kinase CK2 and their functional links. Prog Nucleic Acid Res Mol Biol. 2003;74:239–73.PubMedCrossRefGoogle Scholar
  25. Rabalski A, Gyenis L, Litchfield DW. Molecular Pathways: emergence of protein kinase CK2 (CSNK2) as a potential target to inhibit survival and DNA damage response and repair pathways in cancer cells. Clin Cancer Res. 2016;22:2840–7.PubMedCrossRefGoogle Scholar
  26. Ruzzene M, Pinna LA. Addiction to protein kinase CK2: a common denominator of diverse cancer cells? Biochim Biophys Acta. 2010;1804:499–504.PubMedCrossRefGoogle Scholar
  27. Sarno S, Pinna LA. Protein kinase CK2 as a druggable target. Mol BioSyst. 2008;4:889–94.PubMedCrossRefGoogle Scholar
  28. Scaglioni PP, Yung TM, Cai LF, Erdjument-Bromage H, Kaufman AJ, Singh B, et al. A CK2-dependent mechanism for degradation of the PML tumor suppressor. Cell. 2006;126:269–83.PubMedCrossRefGoogle Scholar
  29. Solares AM, Santana A, Baladrón I, Valenzuela C, González CA, Díaz A, Castillo D, Ramos T, Gómez R, Alonso DF, Herrera L, Sigman H, Perea SE, Acevedo BE, López-Saura P. Safety and preliminary efficacy data of a novel casein kinase 2 (CK2) peptide inhibitor administered intralesionally at four dose levels in patients with cervical malignancies. BMC Cancer. 2009;9:146.Google Scholar
  30. St-Denis NA, Litchfield DW. Protein kinase CK2 in health and disease: From birth to death: the role of protein kinase CK2 in the regulation of cell proliferation and survival. Cell Mol Life Sci. 2009;66:1817–29.PubMedCrossRefGoogle Scholar
  31. St-Denis N, Bailey ML, Parker EL, Vilk G, Litchfield DW. Localization of phosphorylated CK2alpha to the mitotic spindle requires the peptidyl-prolyl isomerase Pin1. J Cell Sci. 2011;124:2341–8.PubMedCrossRefGoogle Scholar
  32. St-Denis N, Gabriel M, Turowec JP, Gloor GB, Li SS, Gingras AC, Litchfield DW. Systematic investigation of hierarchical phosphorylation by protein kinase CK2. J Proteome. 2015;118:49–62.CrossRefGoogle Scholar
  33. Trembley JH, Wang G, Unger G, Slaton J, Ahmed K. Protein kinase CK2 in health and disease: CK2: a key player in cancer biology. Cell Mol Life Sci. 2009;66:1858–67.PubMedPubMedCentralCrossRefGoogle Scholar
  34. Turowec JP, Duncan JS, French AC, Gyenis L, St-Denis NA, Vilk G, Litchfield DW. Protein kinase CK2 is a constitutively active enzyme that promotes cell survival: strategies to identify CK2 substrates and manipulate its activity in cells. Methods Enzymol. 2010;484:471–93.PubMedCrossRefGoogle Scholar
  35. Turowec JP, Zukowski SA, Knight JD, Smalley DM, Graves LM, Johnson GL, Li SS, Lajoie GA, Litchfield DW. An unbiased proteomic screen reveals caspase cleavage is positively and negatively regulated by substrate phosphorylation. Mol Cell Proteomics. 2014;13:1184097.CrossRefGoogle Scholar
  36. Venerando A, Ruzzene M, Pinna LA. Casein kinase: the triple meaning of a misnomer. Biochem J. 2014;460:141–56.PubMedCrossRefGoogle Scholar
  37. Watanabe N, Arai H, Iwasaki J, Shiina M, Ogata K, Hunter T, Osada H. Cyclin-dependent kinase (CDK) phosphorylation destabilizes somatic Wee1 via multiple pathways. Proc Natl Acad Sci USA. 2005;102:11663–8.PubMedPubMedCentralCrossRefGoogle Scholar
  38. Xu X, Landesman-Bollag E, Channavajhala PL, Seldin DC. Murine protein kinase CK2: gene and oncogene. Mol Cell Biochem. 1999;191:65–74.PubMedCrossRefGoogle Scholar
  39. Zhang C, Vilk G, Canton DA, Litchfield DW. Phosphorylation regulates the stability of the CK2beta subunit. Oncogene. 2002;23:3754–64.CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG 2018

Authors and Affiliations

  • Jacob P. Turowec
    • 1
  • Nicole A. St. Denis
    • 1
  • David W. Litchfield
    • 1
    • 2
    Email author
  1. 1.Department of Biochemistry, Schulich School of Medicine and DentistryThe University of Western OntarioLondonCanada
  2. 2.Department of Oncology, Schulich School of Medicine and DentistryThe University of Western OntarioLondonCanada